Background: Hyperfibrinolysis (HF) is a major contributor to coagulopathy and mortality in trauma patients. This study investigated (i) the rate of HF during the pre-hospital management of patients with multiple injuries and (ii) the effects of pre-hospital tranexamic acid (TxA) administration on the coagulation system.

Methods: From 27 trauma patients with pre-hospital an estimated injury severity score (ISS) ≥16 points blood was obtained at the scene and on admission to the emergency department (ED). All patients received 1 g of TxA after the first blood sample was taken. Rotational thrombelastometry (ROTEM) was performed for both blood samples, and the results were compared. HF was defined as a maximum lysis (ML) >15 % in EXTEM.

Results: The median (min-max) ISS was 17 points (4-50 points). Four patients (15 %) had HF diagnosed via ROTEM at the scene, and 2 patients (7.5 %) had HF diagnosed via ROTEM on admission to the ED. The median ML before TxA administration was 11 % (3-99 %) vs. 10 % after TxA administration (4-18 %; p > 0.05). TxA was administered 37 min (10-85 min) before ED arrival. The ROTEM results before and after TxA administration did not significantly differ. No adverse drug reactions were observed after TxA administration.

Discussion: HF can be present in severely injured patients during pre-hospital care. Antifibrinolytic therapy administered at the scene is a significant time saver. Even in milder trauma fibrinogen can be decreased to critically low levels. Early administration of TxA cannot reverse or entirely stop this decrease.

Conclusions: The pre-hospital use of TxA should be considered for severely injured patients to prevent the worsening of trauma-induced coagulopathy and unnecessarily high fibrinogen consumption.

Trial Registration: ClinicalTrials.gov ID NCT01938768 (Registered 5 September 2013).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057484PMC
http://dx.doi.org/10.1186/s13049-016-0314-4DOI Listing

Publication Analysis

Top Keywords

txa administration
16
patients
9
txa
9
tranexamic acid
8
patients multiple
8
multiple injuries
8
injuries effects
8
rotational thrombelastometry
8
trauma patients
8
patients pre-hospital
8

Similar Publications

Reduction mammaplasty is a common, elective, and safe operation, usually executed in healthy patients. Nonetheless, postoperative complications like bleeding and seroma formation can occur and significantly complicate the postoperative course. Tranexamic acid (TXA), a commonly used antifibrinolytic drug, offers a novel approach to reduce these complications.

View Article and Find Full Text PDF

Background: The relative efficacies of topical and intravenous tranexamic acid (TXA) in spinal surgery remain controversial. This meta-analysis aimed to compare the efficacy and safety of topical versus intravenous TXA in spinal surgery, with a particular focus on the impacts on intraoperative blood loss (IBL) and associated outcomes.

Methods: We searched the PubMed, EMBASE, Medline, and Cochrane Library databases to identify all literature related to topical and intravenous TXA in spinal surgery.

View Article and Find Full Text PDF

The Impact of Tranexamic Acid Administration in Reduction Mammaplasty: A Systematic Review.

Ann Plast Surg

December 2024

Plastic, Reconstructive and Aesthetic Surgery Department and Burn Unit, São João University Hospital, Porto, Portugal.

Background: Previous studies demonstrated the effectiveness and safety of tranexamic acid (TXA) in several surgical specialties. Recent publications suggested that TXA may also be beneficial in plastic surgery, including breast procedures.

Objective: The aim of this study is to evaluate the impact of TXA in reduction mammaplasty by assessing several intraoperative and postoperative outcomes and the safety of its administration.

View Article and Find Full Text PDF

The aim of this study was to test whether there is a necessity for routine postoperative laboratory testing in patients undergoing primary elective unilateral total knee arthroplasty (TKA), with the administration of Tranexamic Acid (TXA) and without the use of tourniquet. : This observational, retrospective cohort study was conducted at Meir Medical Center. The data were collected in 2018-2022.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the use and safety of intravenous tranexamic acid (TXA) in patients undergoing surgery for intracranial meningiomas, focusing on how different doses affected outcomes.
  • A total of six randomized controlled trials with 881 patients were analyzed, revealing that TXA significantly reduced intraoperative blood loss, blood transfusion rates, surgery duration, and hospital stay lengths, but did not increase postoperative complications.
  • The findings suggested that a preoperative dose of 20 mg/kg with an intraoperative maintenance dose was effective in minimizing blood loss, although further research is needed to confirm these observations and optimize dosing strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!